Clinical trials: Severe Asthma
Asthma
Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics
Asthmatics who are significantly overweight tend to have more severe symptoms, more flare ups, and are more likely to have poorly-controlled asthma when compared to other asthmatics.
- Trial name
- GLITZ Asthma (NCT00634036)
- Testing
- pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Fernando Holguin
Asthma
Prednisolone Pharmacokinetics in Severe Asthma
The purpose of the study is to evaluate whether severe asthmatic subjects have abnormal prednisolone absorption, and how this might affect the anti-inflammatory effects of prednisolone. The aims of the study are 1.
- Trial name
- NCT00662298
- Testing
- prednisolone
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Imperial College London
Moderate to Severe Asthma
Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics
Purpose: To determine if inhaled hypertonic saline (HS) accelerates airway mucociliary clearance (MCC) in well-controlled moderate to severe asthmatics.
- Trial name
- NCT03556683
- Testing
- 3% Hypertonic Saline, 7% Hypertonic Saline, Salbutamol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill
Eosinophils, Asthma
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and…
- Trial name
- NCT03052725
- Testing
- reslizumab
- Where
- 134 sites in United States, Belgium and 11 more
- Volunteers
- 391 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications
The primary objective of this study is to evaluate the dose response, efficacy and safety of 4 different doses of fluticasone propionate (50, 100, 200, and 400mcg) delivered as Fluticasone Spiromax® Inhalation Powder (Fp…
- Trial name
- NCT01576718
- Testing
- Fp MDPI, Flovent Diskus, albuterol/salbutamol
- Where
- 300 sites in United States, Australia and 17 more
- Volunteers
- 889 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma
The overall goal of this study is to understand biological responses related to dupilumab treatment among severe asthma patients. Not all asthma is the same, and characteristics of asthma vary from person to person.
- Trial name
- NCT05036733
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan
Asthma
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks.
- Trial name
- NCT00079937
- Testing
- Omalizumab, Fluticasone
- Where
- 56 sites in United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Churg-Strauss Syndrome, Eosinophilic Asthma
Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
In this project the investigators will look for auto-antibodies to relevant proteins both in native form and importantly in post-translationally modified forms.
- Conditions
- Churg-Strauss Syndrome, Eosinophilic Asthma, Eosinophilic Esophagitis, Eosinophilic Pneumonia
- Trial name
- IDEA (NCT04671446)
- Testing
- Autoantibody ELISA, Granulocyte Immunofluorescence
- Where
- 2 sites in United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Asthma
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants…
- Trial name
- NCT01312961
- Testing
- Dupilumab, Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy
- Where
- 50 sites in United States
- Volunteers
- 104 people
- Sponsor
- Sanofi
Asthma
Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
The aim of this trial is to evaluate the safety and efficacy of 2.5 and 5 µg tiotropium over a 52-week treatment period as compared to placebo.
- Trial name
- NCT01340209
- Testing
- Tiotropium Respimat
- Where
- 55 sites in Japan
- Volunteers
- 285 people
- Sponsor
- Boehringer Ingelheim
Moderate-to-Severe Asthma
Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.
- Trial name
- KB003-04 (NCT01603277)
- Testing
- Anti-GM-CSF Monoclonal Antibody 400mg
- Where
- 70 sites in United States, Australia and 4 more
- Volunteers
- 160 people
- Sponsor
- Humanigen, Inc.
Asthma, Major Depressive Disorder
Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators
The investigators propose a one-year, repeated measures, within-subject design to examine the impact of improved caregiver depression on child asthma outcomes.
- Trial name
- NCT02809677
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 205 people
- Sponsor
- University of Texas Southwestern Medical Center
Asthma Childhood
Ideal Steroids for Asthma Treatment in the PICU
Determine if differences in (1) pediatric intensive care unit length of stay, (2) continuous nebulized albuterol duration, and (3) a composite outcome of advanced asthma therapy incidence including use of non-invasive ventilation…
- Trial name
- iSTAT PICU (NCT03900624)
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Johns Hopkins All Children's Hospital
Asthma
A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.
- Trial name
- SWIFT-2 (NCT04718103)
- Testing
- GSK3511294
- Where
- 129 sites in United States, Australia and 9 more
- Volunteers
- 397 people
- Sponsor
- GlaxoSmithKline
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
This study is multicenter, double-blinded parallel group design, where participants with moderate to severe asthma with AFAD will be enrolled.
- Trial name
- NCT03393806
- Testing
- GSK3772847
- Where
- 18 sites in France, Netherlands and 2 more
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
Asthma
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging
This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomography (CT)-derived measurements of pulmonary structure and function using the Functional…
- Trial name
- BURAN (NCT05552508)
- Testing
- Benralizumab
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Asthma
A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.
The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.
- Trial name
- NCT00419952
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
- Where
- 122 sites in United States
- Volunteers
- 742 people
- Sponsor
- AstraZeneca
Asthma
Study in Adult Patients With Moderate to Severe Asthma
This study assessed the influence of pink vs. white pressurized metered-dose inhaler (pMDI) actuators on asthma symptoms perception. There was no prespecified primary objective.
- Trial name
- FEEL (NCT04886999)
- Testing
- Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler A), Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler B)
- Where
- 10 sites in Italy
- Volunteers
- 78 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Indirect Cost of Illness Study of Moderate and Severe Asthma in Quebec
Rationale Asthma is a chronic inflammatory disorder of the airways affecting persons of all ages and is recognized as one of the most common chronic diseases.
- Trial name
- NCT02153346
- Testing
- Valuation of lost productivity questionnaire, Work productivity and activity impairment questionnaire
- Where
- Canada
- Volunteers
- 101 people
- Sponsor
- GlaxoSmithKline